🇺🇸 FDA
Patent

US 11331332

Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors

granted A61KA61K31/7105

Quick answer

US patent 11331332 (Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue May 17 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 12 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7105